LUNG CANCER (NSCLC)

This phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without t…

This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and can kill more cancer cells while causing fewer side effects than standard IV chemo. The study will enr…

This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two dr…

This study is for people with a specific type of lung cancer (EGFR-positive adenocarcinoma) that has spread to the lining of the chest, causing fluid buildup. Researchers are testing whether combining a daily targeted pill (furmonertinib) with focused chest radiation can safely c…

This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the …

This Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. …

This phase II trial tests the drug cemiplimab, an immunotherapy, given before and after surgery for people with early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. About 33 participants will receive cemiplimab for three cycles, then undergo surg…

This study compares two treatments for high-risk patients with early-stage non-small cell lung cancer: minimally invasive surgery (wedge resection) and stereotactic body radiation therapy (SBRT). The goal is to see which approach leads to longer disease-free survival and better q…

This Phase 2 trial tests a drug called ivonescimab, either alone or with chemotherapy, in people with advanced non-small cell lung cancer that has certain genetic changes. The study aims to see if the treatment can shrink tumors and control the cancer. About 46 participants will …

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study looks back at medical records of 600 Chinese patients with advanced non-small cell lung cancer that has a KRAS G12C mutation. All patients took the drug IBI351 between August 2024 and August 2025. Researchers will check how many patients' tumors shrank or disappeared, …

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…

This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The …

This study looks at sputum and blood samples from 50 adults with advanced non-small cell lung cancer who are starting immunotherapy. Researchers want to find immune cell changes that could predict which patients will respond well to treatment. The goal is to better understand the…

This study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip stre…

This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…

This study uses artificial intelligence to analyze CT scans, pathology slides, and genetic reports from 1,000 lung cancer patients with EGFR mutations. The goal is to build a model that predicts how well targeted therapy will work after surgery. If successful, it could help docto…

This study will use artificial intelligence and 3D CT scans to predict how well a person's lungs will work after different treatments for early-stage lung cancer. About 192 adults with stage IA non-small cell lung cancer will be followed for two years after surgery or a minimally…